ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises